Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Convertible Debt (2016 - 2019)

Historic Convertible Debt for Ani Pharmaceuticals (ANIP) over the last 11 years, with Q3 2019 value amounting to $117.6 million.

  • Ani Pharmaceuticals' Convertible Debt fell 1232.91% to $117.6 million in Q3 2019 from the same period last year, while for Sep 2019 it was $117.6 million, marking a year-over-year decrease of 1232.91%. This contributed to the annual value of $112.5 million for FY2018, which is 1228.08% down from last year.
  • Ani Pharmaceuticals' Convertible Debt amounted to $117.6 million in Q3 2019, which was down 1232.91% from $115.9 million recorded in Q2 2019.
  • In the past 5 years, Ani Pharmaceuticals' Convertible Debt ranged from a high of $134.1 million in Q3 2018 and a low of $112.2 million during Q1 2015
  • For the 5-year period, Ani Pharmaceuticals' Convertible Debt averaged around $120.2 million, with its median value being $117.6 million (2019).
  • Per our database at Business Quant, Ani Pharmaceuticals' Convertible Debt skyrocketed by 646.42% in 2015 and then plummeted by 1232.91% in 2019.
  • Over the past 5 years, Ani Pharmaceuticals' Convertible Debt (Quarter) stood at $113.4 million in 2015, then rose by 6.36% to $120.6 million in 2016, then grew by 6.27% to $128.2 million in 2017, then dropped by 12.28% to $112.5 million in 2018, then grew by 4.56% to $117.6 million in 2019.
  • Its Convertible Debt stands at $117.6 million for Q3 2019, versus $115.9 million for Q2 2019 and $114.2 million for Q1 2019.